On 25 June 2024, Novo Nordisk announced its plan to significantly boost its investment in manufacturing in 2024, allocating USD $6.8 billion towards production. This is up from USD $3.9 billion the previous year.
The plan includes a USD $4.1 billion investment to build a second manufacturing facility in Clayton, North Carolina, expanding its capacity to produce injectable treatments for obesity and chronic diseases. The new facility will add 1.4 million square feet of production space and create 1,000 new jobs.
This news follows Ginkgo Bioworks’ announcement on 10 April 2024 of an expansion of its partnership with global healthcare leader, Novo Nordisk.